JP2014526559A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526559A5
JP2014526559A5 JP2014531996A JP2014531996A JP2014526559A5 JP 2014526559 A5 JP2014526559 A5 JP 2014526559A5 JP 2014531996 A JP2014531996 A JP 2014531996A JP 2014531996 A JP2014531996 A JP 2014531996A JP 2014526559 A5 JP2014526559 A5 JP 2014526559A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
mab
efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014531996A
Other languages
English (en)
Other versions
JP6204915B2 (ja
JP2014526559A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/056492 external-priority patent/WO2013043973A2/en
Publication of JP2014526559A publication Critical patent/JP2014526559A/ja
Publication of JP2014526559A5 publication Critical patent/JP2014526559A5/ja
Application granted granted Critical
Publication of JP6204915B2 publication Critical patent/JP6204915B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (15)

  1. 人対象における悪液質を治療するための医薬組成物であって、薬学的に許容し得る担体と前記対象における悪液質の少なくとも１つの症状を低減するために有効な抗−ＩＬ−１α Ａｂの量を含むことを特徴とする医薬組成物。
  2. 請求項１に記載の医薬組成物において、前記抗−ＩＬ−１α ＡｂがｍＡｂであることを特徴とする医薬組成物。
  3. 請求項２に記載の医薬組成物において、前記ｍＡｂがＩｇＧ１であることを特徴とする医薬組成物。
  4. 請求項２に記載の医薬組成物において、前記ｍＡｂが、ＭＡＢｐ１の相補性決定領域を含むことを特徴とする医薬組成物。
  5. 請求項２に記載の医薬組成物において、前記ｍＡｂがＭＡＢｐ１であることを特徴とする医薬組成物。
  6. 請求項１に記載の医薬組成物において、前記対象の除脂肪体重を増加させる効能を有することを特徴とする医薬組成物。
  7. 請求項１に記載の医薬組成物において、前記対象の体重を増加させる効能を有することを特徴とする医薬組成物。
  8. 請求項１に記載の医薬組成物において、前記対象の食欲を改善する効能を有することを特徴とする医薬組成物。
  9. 請求項１に記載の医薬組成物において、末期癌を有する人を対象とすることを特徴とする医薬組成物。
  10. 請求項１に記載の医薬組成物において、前記対象の筋肉量を増加させる効能を有することを特徴とする医薬組成物。
  11. 請求項１に記載の医薬組成物において、前記対象の除脂肪体重を増加させる効能を有することを特徴とする医薬組成物。
  12. 悪液質を有する哺乳動物対象における寿命を延ばすための医薬組成物であって、薬学的に許容し得る担体と、前記対象の前記予測された寿命に比較して少なくとも１０％まで前記対象の前記寿命を延ばすために有効な抗−ＩＬ−１α Ａｂの量を含むことを特徴とする医薬組成物。
  13. 請求項１２に記載の医薬組成物において、前記抗−ＩＬ−１α ＡｂがｍＡｂであることを特徴とする医薬組成物。
  14. 請求項１３に記載の医薬組成物において、前記ｍＡｂが、ＭＡＢｐ１であることを特徴とする医薬組成物。
  15. 請求項１２に記載の医薬組成物において、末期癌を有する人を対象とすることを特徴とする医薬組成物。
JP2014531996A 2011-09-23 2012-09-21 悪液質治療 Active JP6204915B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161538309P 2011-09-23 2011-09-23
US61/538,309 2011-09-23
PCT/US2012/056492 WO2013043973A2 (en) 2011-09-23 2012-09-21 Cachexia treatment

Publications (3)

Publication Number Publication Date
JP2014526559A JP2014526559A (ja) 2014-10-06
JP2014526559A5 true JP2014526559A5 (ja) 2015-10-29
JP6204915B2 JP6204915B2 (ja) 2017-09-27

Family

ID=47911521

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014531996A Active JP6204915B2 (ja) 2011-09-23 2012-09-21 悪液質治療

Country Status (16)

Country Link
US (2) US9809649B2 (ja)
EP (1) EP2750709B1 (ja)
JP (1) JP6204915B2 (ja)
KR (1) KR102039198B1 (ja)
CN (2) CN108404127A (ja)
AU (1) AU2012312225B2 (ja)
CA (1) CA2849710C (ja)
DK (1) DK2750709T3 (ja)
ES (1) ES2695102T3 (ja)
HK (1) HK1199616A1 (ja)
IL (1) IL231622B (ja)
MX (1) MX356808B (ja)
PT (1) PT2750709T (ja)
RU (1) RU2622021C2 (ja)
WO (1) WO2013043973A2 (ja)
ZA (1) ZA201402057B (ja)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107596365A (zh) 2010-06-18 2018-01-19 埃克斯生物科技公司 关节炎治疗
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
RU2622021C2 (ru) 2011-09-23 2017-06-08 ИксБиотеч, Инк. Лечение кахексии
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
US10485502B2 (en) * 2016-12-20 2019-11-26 General Electric Company System and method for assessing muscle function of a patient
CA3053231A1 (en) 2017-02-16 2018-08-23 Xbiotech Inc. Treatment of hidradenitis suppurativa
US10975146B2 (en) 2018-06-29 2021-04-13 Cedars-Sinai Medical Center Interleukin-1 inhibition for combination treatment of pancreatic cancer

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5672347A (en) 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4965198A (en) 1985-12-24 1990-10-23 Konica Corporation Monoclonal antibody and method of manufacturing hybridoma producing the same
DE3631229A1 (de) 1986-09-13 1988-03-24 Basf Ag Monoklonale antikoerper gegen humanen tumornekrosefaktor (tnf) und deren verwendung
DK590387A (da) 1986-11-13 1988-05-14 Otsuka Pharma Co Ltd Antistoffer mod interleukin-1
US5034316A (en) 1987-03-30 1991-07-23 The Regents Of The University Of California In vitro human monoclonal IgG rheumatoid factor autoantibody
FR2640146B1 (fr) 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04504253A (ja) 1989-03-27 1992-07-30 セントカー・インコーポレーテツド ＩｇＭ抗体の安定化のための配合物
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
AU5355094A (en) 1992-10-14 1994-05-09 Sterling Winthrop Inc. Therapeutic and diagnostic imaging compositions and methods
DK0614984T4 (da) 1993-03-05 2010-12-20 Bayer Healthcare Llc Humane monoklonale anti-TNF-alfa-antistoffer
US5959085A (en) 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (en) 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
GB9509620D0 (en) 1995-05-12 1995-07-05 Nat Blood Authority Transepithelial transport of molecular species
US6140470A (en) 1995-06-30 2000-10-31 Yale University Human monoclonal anti-tumor antibodies
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
SE9802402D0 (sv) 1998-07-03 1998-07-03 Karolinska Innovations Ab Method of diagnosing cardiovascular disease and early atherosclerosis
US20030040617A9 (en) 1999-03-12 2003-02-27 Rosen Craig A. Nucleic acids, proteins and antibodies
US20030232054A1 (en) 2000-01-25 2003-12-18 Tang Y. Tom Novel nucleic acids and polypeptides
US6623736B2 (en) 2000-05-02 2003-09-23 Edward L. Tobinick Interleukin antagonists for the treatment of neurological, retinal and muscular disorders
AU2007202323C1 (en) 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
JPWO2002033094A1 (ja) 2000-10-19 2004-10-21 協和醗酵工業株式会社 Ｖｐｌｆの活性を阻害する抗体
US20030026806A1 (en) 2000-10-27 2003-02-06 Amgen Inc. Antibodies and other selective IL-1 binding agents that allow binding to IL-1 receptor but not activation thereof
US7273888B2 (en) 2001-11-16 2007-09-25 Als Therapy Development Foundation, Inc. Use of difluoromethylornithine (DFMO) for the treatment of amyotrophic lateral sclerosis
EA018072B1 (ru) 2002-09-06 2013-05-30 Амджен Инк. Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение
JP4450644B2 (ja) 2003-03-03 2010-04-14 日本化薬株式会社 Ａｍｆ類を有効成分とする医薬製剤
WO2004100987A2 (en) 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US7799327B2 (en) 2003-12-24 2010-09-21 Henry John Smith Autoantibodies utilized as carrier agents for pharmaceutical compounds used in cancer treatment
US7105183B2 (en) 2004-02-03 2006-09-12 The Regents Of The University Of California Chlorite in the treatment of neurodegenerative disease
JP5149001B2 (ja) 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US20050276807A1 (en) 2004-06-15 2005-12-15 Advanced Biotherapy, Inc. Treatment of acne
WO2006036936A2 (en) 2004-09-27 2006-04-06 Bridge Pharma, Inc. The s-isomer of 2-{2-[n-(2-indanyl)-n-phenylamino]ethyl}piperidine and other dermal anesthetic agents
PL1819359T3 (pl) 2004-12-09 2015-08-31 Janssen Biotech Inc Immunokoniugaty skierowane przeciw integrynie, metody ich wytwarzania oraz ich zastosowanie
ATE470151T1 (de) 2005-08-02 2010-06-15 Xbiotech Inc Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
US20090215992A1 (en) 2005-08-19 2009-08-27 Chengbin Wu Dual variable domain immunoglobulin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20080047564A (ko) 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
RU2008144802A (ru) 2006-04-14 2010-05-20 Новартис АГ (CH) Применение антител против ил-1 для лечения глазных расстройств
WO2007132338A2 (en) 2006-05-15 2007-11-22 Xbiotech Inc. IL-1α IMMUNIZATION INDUCES AUTOANTIBODIES PROTECTIVE AGAINST ATHEROSCLEROSIS
US20110008282A1 (en) 2006-05-15 2011-01-13 Xbiotech, Inc. IL-1alpha immunization induces autoantibodies protective against atherosclerosis
PL2109623T3 (pl) 2006-05-22 2012-03-30 Xbiotech Inc Leczenie nowotworu przeciwciałami przeciw il-1
MX2008015132A (es) 2006-05-30 2008-12-10 Genentech Inc Anticuerpos e inmunoconjugados y sus usos.
EP2114443A4 (en) 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
EP2265125B1 (en) 2008-04-15 2019-08-14 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
MY154067A (en) * 2008-05-30 2015-04-30 Xbiotech Inc IL-1a ABS AND METHODS OF USE
JP5976319B2 (ja) 2008-09-12 2016-08-23 エックスバイオテク，インコーポレイテッドＸｂｉｏｔｅｃｈ，Ｉｎｃ． 病原性単球の標的化
PE20120586A1 (es) * 2009-01-29 2012-06-17 Abbott Lab Proteinas de union a il-1
JP2013507929A (ja) 2009-10-15 2013-03-07 アボット・ラボラトリーズ Ｉｌ−１結合蛋白質
CN107596365A (zh) 2010-06-18 2018-01-19 埃克斯生物科技公司 关节炎治疗
KR101910760B1 (ko) 2010-08-23 2018-10-22 엑스바이오테크, 인크. 종양성 질병들에 대한 치료
EP3417879A1 (en) 2011-04-01 2018-12-26 XBiotech, Inc Treatment for dermatological pathologies
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
RU2622021C2 (ru) 2011-09-23 2017-06-08 ИксБиотеч, Инк. Лечение кахексии
US20130195877A1 (en) 2012-01-31 2013-08-01 Xbiotech, Inc. Treatment of cachexia by targeting interleukin-1 beta
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
CA2886747C (en) 2012-10-04 2023-12-05 Xbiotech Inc. Treating vascular disease and complications thereof
CA2886757C (en) 2012-10-04 2022-04-05 Xbiotech Inc. Treatment of anxiety with il1.alpha. antagonist

Similar Documents

Publication Publication Date Title
JP2014526559A5 (ja)
RS54707B1 (en) TREATMENT OF CROWN LAKVINIMOD DISEASE
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
SI2205244T1 (sl) Postopki dajanja N-(5-terc.-butil-izoksazol-3-il)-N'-(4-(7-(2-morfolin- 4-il-etoksi-)imidazo-2,1-b)-(1,3)-benzotiazol-2-il)-fenil)sečnine za zdravljenje proliferativne bolezni
EA201170018A1 (ru) Разагилин для изменения течения болезни паркинсона
NZ707377A (en) Combination therapy methods for treating proliferative diseases
UA112288C2 (uk) Склад антитіла, що специфічно зв'язує рецептор а іl-17, і терапевтичні режими
JP2010222367A5 (ja)
NZ606993A (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
JP2010522242A5 (ja)
WO2015085143A3 (en) Therapeutic agents for skin diseases and conditions
JP2015515475A5 (ja)
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
IN2014DN07149A (ja)
MX358491B (es) Una composicion farmacéutica para tratar cáncer, que comprende un conjugado de interferón alfa.
EA200802412A1 (ru) Терапевтические комбинации для сопровождающихся болью медицинских состояний
MX2014013039A (es) Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
RU2014111662A (ru) Лечение кахексии
MX2012008652A (es) Terapias para tratar infeccion por virus de hepatitis c.
MX2016011333A (es) Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina.
EP3238726A3 (en) Composition comprising interferon gamma and an hdac inhibitor or gonadotropin receptor signalling hormone
JP2015531396A5 (ja)
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
BRPI1008103A2 (pt) " peptídeo de cadeia curta isolado, composição farmacêutica, compostos, método de evitar ou tratar doenças, medicamento para tratar/ reduzir condições médicas e uso dos compostos "